Radiology

#JustGo Campaign PSA Encourages Heart Valve Patients To Follow Up on Care

Tuesday, June 15, 2021 - 3:30pm

Because of the COVID-19 pandemic, many heart valve patients have been unable or unwilling to follow up on their diagnosis and schedule necessary procedures.

Key Points: 
  • Because of the COVID-19 pandemic, many heart valve patients have been unable or unwilling to follow up on their diagnosis and schedule necessary procedures.
  • To address this potential health crisis, Heart Valve Voice US launched the #JustGo campaign earlier this year with aggressive social media and digital outreach.
  • Heart valve disease disproportionately affects older people, said John Lewis, Executive Director, Heart Valve Voice US.
  • Heart Valve Voice US is a nonprofit patient advocacy organization that provides a united voice for people living with heart valve disease.

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Tuesday, June 15, 2021 - 2:21pm

Hyperfine, Inc., creators of the worlds first portable magnetic resonance imaging device, has named Scott Huennekens Executive Chairman of the Board.

Key Points: 
  • Hyperfine, Inc., creators of the worlds first portable magnetic resonance imaging device, has named Scott Huennekens Executive Chairman of the Board.
  • View the full release here: https://www.businesswire.com/news/home/20210615005262/en/
    Scott Huennekens is named Executive Chairman of the Board at Hyperfine.
  • As Executive Chairman, he will partner with recently announced President and CEO Dave Scott to build Hyperfine into a leading ecosystem in the brain and beyond.
  • Dave Scott, President and CEO of Hyperfine, who previously worked with Mr. Huennekens at Verb Surgical/Google added, Scott has made a broad impact across the healthcare industry and is a practiced and experienced executive chairman.

TeleRay Advises that POCUS Images Need to be Stored Properly for Billing, Access, and to Avoid HIPAA Fines

Tuesday, June 15, 2021 - 1:43pm

In other words, POCUS means faster care since evaluation is typically done by a non-radiologist.

Key Points: 
  • In other words, POCUS means faster care since evaluation is typically done by a non-radiologist.
  • Typically, when the scanners hard drive fills up, it defaults to 'FIFO' or first-in-first-out protocol and begins automatically deleting studies.
  • Ensuring reliable, high-quality connection and fast access to additional data and images are key, which TeleRay resolves through cellular back-up where required.
  • About TeleRay: TeleRay is a technology leader with the only telehealth radiology platform for the management and distribution of medical images and patient information.

Market Leader Eon Rolls Out A First-Of-Its-Kind Breast Software Solution

Tuesday, June 15, 2021 - 1:36pm

DENVER, June 15, 2021 /PRNewswire/ --Denver-based healthtech leader Eon announces the launch of its latest Essential Patient Management (EPM) module, Eon EPM Breast .

Key Points: 
  • DENVER, June 15, 2021 /PRNewswire/ --Denver-based healthtech leader Eon announces the launch of its latest Essential Patient Management (EPM) module, Eon EPM Breast .
  • Eon is the only market available vendor to offer the necessary technology to identify patients with incidental breast findings from radiology examswith 95% accuracyand track their follow-up.
  • Considering only 50% of all incidental breast patients are screening-eligible, the incidental identification and patient management capabilities of EPM Breast set it apart as healthcare's only software option for a comprehensive breast program.
  • Eon EPM Breast is the latest EPM solution for multiple disease states, including breast, lung, aneurysms, pancreas, thyroid, adrenal, renal, and liver.

Attralus Announces Presentation of Clinical Data on AT-01, a Novel Diagnostic for Systemic Amyloidosis, at the 2021 Society of Nuclear Molecular Imaging Meeting

Tuesday, June 15, 2021 - 12:00pm

An oral presentation and posters described results from a clinical study evaluating AT-01 (124I-p5+14), a novel, radiolabeled, synthetic amyloid-targeting peptide designed for imaging systemic amyloid deposits.

Key Points: 
  • An oral presentation and posters described results from a clinical study evaluating AT-01 (124I-p5+14), a novel, radiolabeled, synthetic amyloid-targeting peptide designed for imaging systemic amyloid deposits.
  • Currently, a definitive diagnosis of systemic amyloidosis is often made following histological evaluation of a tissue biopsy, said Dr. Wall.
  • In addition, this imaging modality may provide further clinical information to help improve patient management and disease understanding.
  • Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis.

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

Tuesday, June 15, 2021 - 1:00pm

RayzeBio, Inc., which is discovering and developing a broad pipeline of innovative targeted radiopharmaceutical drugs for cancer, today announced a $108 million Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.

Key Points: 
  • RayzeBio, Inc., which is discovering and developing a broad pipeline of innovative targeted radiopharmaceutical drugs for cancer, today announced a $108 million Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
  • The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated, said Ken Song, M.D., president and CEO of RayzeBio.
  • With over $258 million of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.
  • RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes.

ITM Appoints Dr. Klaus Maleck as Chief Financial Officer

Tuesday, June 15, 2021 - 10:00am

ITM AG , a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Klaus Maleck to its leadership team as Chief Financial Officer (CFO) of the ITM Group.

Key Points: 
  • ITM AG , a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Klaus Maleck to its leadership team as Chief Financial Officer (CFO) of the ITM Group.
  • We welcome Klaus who brings a significant track record of corporate financial management and operations in private as well as public companies.
  • Prior to joining ITM, Dr. Maleck held leading executive roles with growing responsibilities within the biopharmaceutical industry including the roles of Chief Financial Officer and Chief Business Officer at Evotec AG where he successfully delivered on key corporate development activities including a Nasdaq listing.
  • Before his tenure at Evotec, Dr. Maleck served as Chief Financial Officer and Vice President Business Development of BioGeneriX AG, which he co-founded in 2000.

Kheiron’s AI Breast Screening Solution Mia® Receives Regulatory Clearance in Australia and New Zealand

Tuesday, June 15, 2021 - 12:25am

Mia is being launched in partnership with AI Advance , an AI consulting services and software distribution company for the medical imaging industry based in Australia and New Zealand.

Key Points: 
  • Mia is being launched in partnership with AI Advance , an AI consulting services and software distribution company for the medical imaging industry based in Australia and New Zealand.
  • Our mission at Kheiron is to support breast screening professionals in the fight against breast cancer with proven and effective AI-enabled tools, states Alex Hamlow, Kheirons chief commercial officer.
  • Were excited that Mia is the first AI independent reader solution available for use within the breast screening community in Australia and New Zealand.
  • We are looking forward to bringing the Mia solution to the breast screening community throughout Australia and New Zealand, comments Peter Rady, director and co-founder of AI Advance.

Insights on the Medical X-Ray Detectors Global Market to 2029 - A New Generation of X-ray Detectors are Driving Growth - ResearchAndMarkets.com

Monday, June 14, 2021 - 3:25pm

This innovation forced many key players to develop extremely sensitive X-ray detectors that will reduce the radiation dose.

Key Points: 
  • This innovation forced many key players to develop extremely sensitive X-ray detectors that will reduce the radiation dose.
  • The X-ray photon energy is vital part of X-ray detectors as X-ray absorption coefficients of the various elements of the system are majorly relied on it.
  • What are the current market dynamics and opportunities for the key companies operational in medical X-ray detectors market?
  • What is the competitive landscape of medical X-ray detectors market?

Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting

Monday, June 14, 2021 - 1:30pm

A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.

Key Points: 
  • A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.
  • The performance of PYLARIFY for imaging of patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels.
  • 18 F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy J Nucl Med 2020 Jun;61(6):881-889. doi: 10.2967/jnumed.119.234799.
  • 3Werner et al 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging Theranostics 2020; 10(1):1-16. doi:10.7150/thno.37894.